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Abstract
As carbohydrate-deficient glycoprotein syndromes (CDGS) are multisystemic disorders with impaired central nervous
function in nearly all cases, we tested isoforms of L-trace protein (LTP), a ‘brain-type’ glycosylated protein in cerebrospinal
fluid (CSF) of nine patients with the characteristic CDGS type I pattern of serum transferrin. Whereas the serum transferrin
pattern did not discriminate between the various subtypes of CDGS type I (CDGS type Ia, type Ic and patients with
unknown defect), LTP isoforms of CDGS type Ia patients differed from that of the other CDGS type I patients. The
percentage of abnormal LTP isoforms correlated with the severity of the neurological symptoms. Furthermore, two patients
are described, who illustrate that abnormal protein N-glycosylation can occur restricted to either the ‘peripheral’ serum or the
central nervous system compartment. This is the first report presenting evidence for an N-glycosylation defect restricted to
the brain. Testing LTP isoforms is a useful tool to detect protein N-glycosylation disorders in the central nervous
system. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
The carbohydrate-de¢cient glycoprotein syn-
dromes (CDGS) are a new group of inherited disor-
ders a¡ecting the synthesis of the asparagine-linked
(N-linked) glycans ¢rst described by Jaeken in 1980
[1]. Based on a di¡erent banding pattern in the iso-
electric focusing (IEF) of serum transferrin due to
the abnormal glycosylation of the oligosaccharide
chains, four types of CDGS (type I^IV) have been
classi¢ed [2^6]. CDGS type I syndromes are de¢ned
by a type I sialotransferrin pattern delineated by in-
creased di- and asialotransferrin and decreased tetra-
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sialotransferrin bands. Among CDGS type I three
di¡erent diseases have been identi¢ed: CDGS type
Ia is caused by phosphomannomutase 2 (PMM 2)
de¢ciency [7] and CDGS type Ib by phosphoman-
nose isomerase (PMI) de¢ciency [8^10]. Both cyto-
solic enzymes catalyse steps in the early glycosylation
pathway. In a group of four patients (children of an
inbred family) and another unrelated child, a defec-
tive glycosyltransferase of the endoplasmic reticulum
(ER) causes the accumulation of dolichol-linked
Man9GlcNAc2. As for historical reasons the classi¢-
cation of CDGS is based on the isoform pattern
observed for transferrin, the disorder is called
CDGS type Ic in this publication and in two earlier
papers [11,12], whereas Ko«rner et al. published their
patient with the same enzyme defect as CDGS type
V [13]. In addition, a number of patients with a
CDGS type I transferrin pattern on IEF but so far
unknown N-glycosylation defect have been identi¢ed.
They are labelled CDGS type Ix.
Beta-trace protein (LTP) is one of the most prom-
inent polypeptide constituents in human cerebrospi-
nal £uid (CSF), detectable in a concentration of
about 8 Wg/ml [14]. This glycoprotein is predomi-
nantly intrathecally synthesised and secreted by
glia-rich fractions of the brain. It is also detectable
in trace amounts in kidney, epididymis and other
organs [15,16]. The structure of the carbohydrate
units of LTP was elucidated only recently. There is
evidence that LTP is ‘brain-type’ glycosylated. This
means that all biantennary N-linked oligosaccharides
are of the complex type and have a high degree of
peripheral fucosylation, high amounts of bisecting N-
acetylglucosamine (GlcNAc) and N-acetylneuraminic
acid (NeuNAc) in K2,3 or K2,6 linkage [17]. In con-
trast to these characteristics of LTP in CSF, periph-
eral fucosylation and bisecting GlcNAc are nearly
absent in serum-type glycoproteins and NeuNAc is
found predominantly in K2,6 linkage [18,19].
CDGS are multisystemic diseases and the common
clinical presentation in the most frequently occurring
CDGS type Ia, but also in CDGS types Ic and Ix, is
moderate to severe cerebral symptoms. Under the
assumption that abnormal glycosylation in brain
may play a role in the pathogenesis of brain dys-
function in CDGS, the question was whether in cer-
tain CDG syndromes the abnormal glycosylation
pattern of serum glycoproteins can be recovered
also in ‘brain-type’ glycosylated glycoproteins such
as LTP. Furthermore, based on the idea that de¢-
cient glycosylation as a cause of brain damage might
be con¢ned to the CNS [20], we tested LTP for
abnormal glycosylation in 500 CSF samples of chil-
dren with impaired cerebral function of unknown
cause.
2. Materials and methods
2.1. Materials
2.1.1. Controls
In 25 age-matched controls CSF was obtained as
part of routine diagnostic procedure. Retro-
spectively, the controls were classi¢ed as suitable
reference subjects because of lack of evidence for
immunological or renal diseases. Appropriate tests
ruled out acute or chronic infectious diseases. Serum
and CSF samples were kept at 380‡C until analy-
sis.
2.1.2. CDGS type Ia, Ic and Ix
Samples of CSF and serum were obtained from
children with CDGS after their parents’ informed
consent. In nine CDGS type I patients (4 type Ia,
1 type Ic and 4 type Ix cases), aged between 3 months
and 7 years, the serum transferrin pattern on IEF
showed the characteristic increase of a- and disialo-
transferrin and decrease of tetrasialotransferrin (Ta-
ble 1). The characteristic abnormalities on IEF were
also demonstrated in the IEF pattern of TBG (thy-
roxine binding globulin) con¢rming a generalised
glycoprotein abnormality (data not shown). A vari-
ant in the protein moiety of transferrin was excluded
by IEF of serum transferrin after neuraminidase
treatment [21]. Four CDGS type Ia patients showed
reduced PMM activity in leukocytes and ¢broblasts
(leukocytes 0.0^0.1 mU/mg protein, ¢broblasts 0.09^
0.57 mU/mg protein, normal ranges: leukocytes
0.41^1.81 mU/mg protein, ¢broblasts 1.27^4.53
mU/mg protein). By SSCP analysis and sequencing
the frequent missense mutation F119L/R141H was
identi¢ed in two patients, and R123Q/R162W was
found in another child [22]. In the fourth subject a
new missense mutation H218L was described in com-
bination with a splice mutation in intron 3. In CDGS
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type Ic and CDGS type Ix cases, PMM and PMI
de¢ciency was excluded by measuring the enzyme
activities in leukocytes and ¢broblasts. Biochemical
and molecular genetic characterisation of the defect
in the glycosylation of dolichol-linked oligosaccha-
rides in the CDGS type Ic family has been described
[11,12]. The basic defect(s) in the CDGS type Ix
cases remain(s) unclear and may turn out to be het-
erogeneous.
In all patients with CDGS type I the CNS was
involved. The neurological abnormalities were highly
variable, ranging from only minor neurological
symptoms to full-blown neuropathology of CDGS
type Ia. Muscular hypotonia, psychomotor retarda-
tion and speech delay were constant features. Over-
all, CDGS type Ia patients presented with more se-
vere neurological symptoms compared to patients
with CDGS type Ic and Ix.
2.1.3. CSF from a patient with other
hypoglycosylation of serum glycoproteins
During the workup of a 21-year-old female (H.K.)
with severe mental retardation and neurological im-
pairment, an abnormal pattern of the serum trans-
ferrin and TBG was obtained on IEF. Also in this
patient, a polymorphism in the transferrin could be
ruled out as an explanation for the abnormal iso-
forms distribution after neuraminidase incubation.
The sialotransferrin pattern showed elevated mono-,
di- and trisialo- and decreased tetrasialotransferrin
bands, by de¢nition a CDGS type II pattern (Table
1). This patient presented with an Angelman-like ap-
pearance, severe developmental and speech delay and
mild epilepsy. Magnetic resonance imaging of the
brain showed no abnormalities.
2.1.4. CSF from children with various neurological
disorders
A total of 500 CSF samples were collected from
children (age 4 months^18 years) with various neuro-
logical symptoms. This material was obtained in the
context of diagnostic investigations and was stored
until analysis at 380‡C. The leading neurological
signs and symptoms included mental and motor re-
tardation, epilepsy and muscular hypotonia.
2.2. Methods
2.2.1. Isoelectric focusing of serum transferrin
IEF of serum transferrin was carried out essen-
tially as described by van Eijk and van Noort [23].
Iron-saturated serum was separated on a hydrated
immobiline gel (pH 4^7) on a Ultrophore system
(Pharmacia, Uppsala, Sweden). After IEF the trans-
ferrin isoforms were visualised by adding rabbit anti
human transferrin antibodies (Dako, Glostrup, Den-
mark) and the gels were stained with Coomassie
blue. The relative amounts of transferrin isoforms
were quanti¢ed with the Ultrascan XL laser densi-
tometer.
2.2.2. IEF of thyroxine-binding globulin in serum
Pure serum was added on a PhastGel (pH 4^6.5,
Pharmacia Biotech) and separated on a PhastSystem.
After addition of rabbit anti-human TBG antibody
(Dako) the TBG pattern was determined by silver
staining.
2.2.3. Phosphomannomutase (PMM)- and
phosphomannose isomerase (PMI)-assay
PMM and PMI activities were measured in leuko-
Table 1
Relative distribution (%) of serum sialotransferrin fractions on isoelectric focusing of di¡erent CDGS type I patients, patients H.K.
and C.V., and healthy controls
Sialotransferrin
fraction
Controls (range)
(n = 30)
CDGS type Ia
(n = 4)
CDGS type Ic
(n = 1)
CDGS type Ix
(n = 4)
H.K. C.V.
0 0.0^2.6 6.6^29.5 10.7 2.2^16.8 2.2 3.6
1 0.0^2.6 1.1^5.4 2.0 1.4^3.3 4.8 2.3
2 1.6^6.1 23.1^37.7 34.9 20.7^42.7 19.2 8.3
3 2.5^15.6 5.9^9.6 6.1 8.0^13.3 28.4 18.2
4 51.2^72.2 20.6^42.3 33.9 22.5^49.0 35.6 48.1
5 12.1^30.8 6.0^14.8 11.0 6.7^14.7 9.8 16.5
6 0.0^9.0 0.0^2.8 1.6 0.0 0.0 2.8
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cytes and/or ¢broblasts, according to the procedure
described by Van Schaftingen and Jaeken [7].
2.2.4. SDS^PAGE and immunoblotting of L-trace
protein
After ethanol precipitation of protein from 100 Wl
CSF and centrifugation, the pellets were dissolved in
20 Wl SDS-bu¡er, containing 10.0 mM Tris^HCl,
1.0 mM EDTA, 2.5% SDS, 5% L-mercaptoethanol
and 0.01% Bromophenol blue, pH 8.0. After heating
(5 min, 95‡C), 4 Wl of the resolved protein were ap-
plied to sodium dodecyl sulfate^polyacrylamide gel
(SDS^PAGE) on a PhastSystem (Pharmacia Bio-
tech), using 20% homogeneous polyacrylamide gels
(PhastGel, Pharmacia Biotech). Focusing was carried
out for 170 Vh at 15‡C. Following transfer to nitro-
cellulose 0.2 Wm membranes (Schleicher and Shuell,
Du«ren), immunodetection of LTP was performed us-
ing a monoclonal mouse antibody against LTP (Prof.
Conradt). The di¡erent fractions were detected by
chemiluminescence with a horseradish peroxidase-
labelled second goat anti-mouse antibody (Pierce,
Hyper¢lm-ECL).
2.2.5. Enzymatic release of N-glycans by
peptide-N-glycosidase F (PNGase F)
Five Wg of puri¢ed human LTP was incubated with
0.2 U of peptide-N-glycosidase F (PNGase F, Boeh-
ringer Mannheim, Germany) at 37‡C [14]. The enzy-
matic reaction was stopped after 30 min, 60 min, 2 h,
4 h and 8 h by freezing at 320‡C. Separation and
immunoblotting of the protein was performed as de-
scribed.
Stepwise cleavage of the N-glycan linkage of gly-
coproteins in puri¢ed human L-TP with peptide-N-
glycosidase F (PNGase F) revealed the formation of
both a- and monoglycosylated forms of LTP with
increasing incubation times (data not shown). This
illustrates that hypoglycosylated isoforms could be
identi¢ed reliably by the method employed. The reli-
ability of the method was further con¢rmed by run-
ning variable amounts (stepwise increase from 20 to
120 Wl) of CSF from a patient with CDGS type Ia.
The abnormal presence of both hypoglycosylated
L-trace isoforms could be shown in all samples.
Quantifying the bands by laser densitometry showed
a stepwise increase of all bands with increasing
amounts of CSF applied (data not shown). The re-
sponse was not fully linear with the amount of pro-
tein applied.
3. Results
3.1. Glycosylation of L-trace protein in normal CSF
The LTP of CSF samples from control individuals
migrated on SDS^PAGE as a single band of about
27 kDa representing the diglycosylated isoform (Fig.
1). The a- and monoglycosylated isoforms of LTP
were not present or below 1% of the amount of the
diglycosylated isoform.
3.2. Glycosylation of L-trace protein in CDGS type I
patients
As shown in Fig. 1, LTP in CSF of all CDGS type
I patients showed the di- (27 kDa) and mono-
(24 kDa) glycosylated isoforms of LTP.
In all CDGS type Ia patients an additional band
was present, representing the aglycosylated (21 kDa)
isoform. The estimated ratio for the di-, mono-
and aglycosylated fraction was 60^65%:30^35%:
5^10%. This aglycosylated band could not be de-
tected in any of the CDGS type Ic and Ix patients.
In these cases the relative distribution of the di-
and monoglycosylated isoforms was 70^85%:15^
30%.
Fig. 1. Western blot analysis of L-trace protein in cerebrospinal £uid from CDGS patients of di¡erent subtypes: A, puri¢ed human
LTP; B, control; C, CDG Ia; D, CDG Ic; E, CDG Ix; F, case H.K.; G, control; H, case C.V. Molecular mass of the isoforms is in-
dicated in kDa.
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3.3. Glycosylation of LTP in subject H.K.
In CSF of the mentally impaired patient H.K. with
clearly abnormal glycosylation of several serum gly-
coproteins (for transferrin fractions see Table 1), a
normal LTP pattern was observed with only diglyco-
sylated LTP (Fig. 1).
3.4. Glycosylation of L-trace protein in subjects with
neurologic disorders
Investigating the glycosylation of LTP in CSF
from 500 children with unexplained disorders of the
CNS, a 7-month-old child (C.V.) was identi¢ed with
an abnormal pattern. In this patient the diglycosyl-
ated (27 kDa) isoform of LTP was reduced whereas
the monoglycosylated (24 kDa) isoform was in-
creased. The relative distribution amounted to
60:40 (Fig. 1) and was di¡erent from the distribution
in patients with CDGS type Ia, Ic and Ix. Careful
reinvestigations on serum glycoproteins (transferrin,
TBG) revealed only marginal abnormalities as com-
pared to normal controls (see Table 1). The clinical
phenotype presented as follows. She was a dysmature
newborn with neonatal seizures. Other major symp-
toms were severe muscular hypotonia, severe feeding
problems, failure to thrive and hypoglycaemic epi-
sodes. Detailed di¡erential diagnostic procedures, in-
cluding comprehensive screening for metabolic disor-
ders, did not lead to a diagnosis. Since the child died
at 8 months of age before this LTP observation was
carried out, no further investigations could be per-
formed. Post-mortem examination revealed liver ¢b-
rosis with transition to cirrhosis and spleen infarc-
tions. Examinations of the CNS showed no
structural abnormalities, and routine light micro-
scopic examinations were also unremarkable.
4. Discussion
The carbohydrate-de¢cient glycoprotein syn-
dromes present as genetic multisystemic disorders
characterised by defective glycosylation of the N-
linked glycan units of a variety of glycoproteins.
The most frequent CDGS type Ia (PMM de¢ciency)
primarily a¡ects the CNS and to a variable degree
also the peripheral nervous system and other organs,
e.g., liver. Neuropathology ¢ndings characteristically
include cerebellar hypoplasia already in newborns
and it is assumed that the regularly occurring arrest
of locomotor ability in early childhood is related to a
postnatal degeneration of infratentorial structures
[24]. Neurological involvement appears less severe
in CDGS type Ic and Ix patients. Abnormal LTP
isoforms in CSF showed disturbed glycosylation in
the CNS in CDGS type Ia but also in CDGS type Ic
and Ix cases. We conclude that protein N-glycosyla-
tion is disturbed in the central nervous system and in
peripheral organs in all CDGS type I subtypes inves-
tigated. Our data on CDGS Ia cases are in accord-
ance with Pohl et al. [25] who demonstrated hypo-
glycosylation of LTP in CSF in CDGS type Ia and
CDGS type II (N-acetylglucosaminyl-transferase II
de¢ciency). Our study extends these ¢ndings to the
CDGS Ic and Ix subtypes.
On the basis of the glycosylation pattern of LTP,
we could distinguish between CDGS type Ia and
other CDGS type I syndromes. The fact that among
all CDGS type I syndromes the aglycosylated
(21 kDa) isoform of LTP is only present in CSF of
patients with CDGS type Ia may indicate that brain-
type glycosylation is more severely impaired in these
cases than in CDGS type Ic or Ix. The biochemical
defect in the brain apparently is more deleterious in
CDGS type Ia than in CDGS Ic and Ix. This is in
line with the clinical observation of more severe neu-
rological disturbances in patients with CDGS type
Ia. In the CDGS type Ia cases there seems to be
less residual £ux through the ‘brain-type’ glycosyla-
tion pathway than in the CDGS type Ic and Ix cases.
This may be explained by a higher local residual
activity of the enzyme(s) involved in the CDGS
type Ic and Ix cases. Of course it cannot be excluded
that patients with more severe mutations in the gene
underlying the CDGS type Ic or Ix defect may be
found that will turn out to have a similar degree of
impairment of the pathway as our CDGS type Ia
cases.
As a result of investigations of N-glycosylation
defects in brain of patients with impairment of the
CNS of unknown aetiology, we identi¢ed one subject
(H.K.) with an abnormal glycosylation pattern of
di¡erent serum glycoproteins but with normal N-gly-
cosylation of LTP in CSF. On the other hand, we
found one subject (C.V.) with only very mild abnor-
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malities of serum glycoproteins and a highly abnor-
mal LTP glycosylation pattern. Known causes for
secondarily impaired glycosylation of serum glyco-
proteins such as alcohol abuse, liver disease, heredi-
tary fructose intolerance and galactosaemia were ex-
cluded [26^28]. In patient C.V. one may assume a
glycosylation defect mainly con¢ned to the CNS
which to our knowledge has not been described so
far. These patients demonstrate that abnormal N-gly-
cosylation of proteins can occur restricted to either
the ‘peripheral’ tissues or the brain.
Although the physiological role of LTP in CSF
and its complete biosynthetic pathway still remain
obscure, di¡erent studies on the biological function,
especially in brain, indicate that it may play a critical
role in regulating the development of neurones and
may participate in myelin metabolism and mainte-
nance [29]. LTP has been discussed as a diagnostic
tool in various disorders. It is a speci¢c marker for
CSF ¢stulae and abnormal concentrations in CSF
have been reported in cerebral infarction, multiple
sclerosis, schizophrenia, paraproteinaemia and ma-
lignancies [30^34]. Whereas previous studies on
LTP so far refer only to quantitative aspects, we
here propose to extend its diagnostic relevance by
studying LTP isoforms to light up impaired N-glyco-
sylation of proteins in the CNS. Several defects in
glycan synthesis have been described recently, and
the number of newly discovered defects will rise as
attention to these disorders increases and new meth-
ods are used. The method for the detection of abnor-
mally glycosylated LTP in CSF is an easy and reli-
able test and can be used in a screening setting. It is
well documented that isoelectric focusing of serum
transferrin is the ideal approach to screen for
CDGS [35]. LTP detection in CSF will not replace
this approach, but this study suggests its diagnostic
value for the screening for N-glycosylation defects in
the CNS. As we have shown, these may even be
exclusively brain tissue speci¢c and would therefore
be missed in the serum transferrin IEF analysis. Fur-
thermore, the degree of LTP hypoglycosylation seems
to re£ect the severity of the CNS involvement.
LTP isoform analysis in CSF should be considered
in the diagnostic workup of patients with an unex-
plained disorder of the CNS.
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